CBT-004
CBT-004 is the first-in-class and first drug therapy to treat vascularized pinguecula. Phase II trial has previously been approved by the FDA. Currently, we are conducting high dose GLP tox study.
Menu
CBT-004 is the first-in-class and first drug therapy to treat vascularized pinguecula. Phase II trial has previously been approved by the FDA. Currently, we are conducting high dose GLP tox study.